Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 286 AL 300

A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned

Modrego P, Lobo A.

Neurodegener Dis Manag. 2019 Jun;9(3):119-121. doi: 10.2217/nmt-2019-0006. Epub 2019 May 22.

Antibiotics, gut microbiota, and Alzheimer's disease

Angelucci F, Cechova K, Amlerova J, Hort J.

J Neuroinflammation. 2019 May 22;16(1):108. doi: 10.1186/s12974-019-1494-4.

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease

Reddy PH, Oliver DM.

Cells. 2019 May 22;8(5):488. doi: 10.3390/cells8050488.

Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies

Yuan NN, Cai CZ, Wu MY, Su HX, Li M, Lu JH.

BMC Complement Altern Med. 2019 May 23;19(1):109. doi: 10.1186/s12906-019-2510-z.

Effects of Vitamin D Use on Outcomes of Psychotic Symptoms in Alzheimer Disease Patients

Wang L, Ying J, Fan P, Weamer EA, DeMichele-Sweet MAA, Lopez OL, Kofler JK, Sweet RA.

Am J Geriatr Psychiatry. 2019 Sep;27(9):908-917. doi: 10.1016/j.jagp.2019.03.016. Epub 2019 Mar 27.

Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review

Yuksel M, Tacal O.

Eur J Pharmacol. 2019 Aug 5;856:172415. doi: 10.1016/j.ejphar.2019.172415. Epub 2019 May 24.

Apolipoprotein B as a New Link Between Cholesterol and Alzheimer Disease

Ishii M.

JAMA Neurol. 2019 Jul 1;76(7):751-753. doi: 10.1001/jamaneurol.2019.0212.

[Drug treatment of Alzheimer's dementia : Status quo and perspectives]

Müller P, Fendt M, Müller NG.

Internist (Berl). 2019 Jul;60(7):761-768. doi: 10.1007/s00108-019-0625-4.

The role of APOE in transgenic mouse models of AD

Balu D, Karstens AJ, Loukenas E, Maldonado Weng J, York JM, Valencia-Olvera AC, LaDu MJ.

Neurosci Lett. 2019 Aug 10;707:134285. doi: 10.1016/j.neulet.2019.134285. Epub 2019 May 28.

Alzheimer's disease: future drug development and the blood-brain barrier

Pardridge WM.

Expert Opin Investig Drugs. 2019 Jul;28(7):569-572. doi: 10.1080/13543784.2019.1627325. Epub 2019 Jun 4.

Associated Factors of Total Costs of Alzheimer's Disease: A Cluster-Randomized Observational Study in China

Yan X, Li F, Chen S, Jia J.

J Alzheimers Dis. 2019;69(3):795-806. doi: 10.3233/JAD-190166.

Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Hampel H, Lista S, Mango D, Nisticò R, Perry G, Avila J, Hernandez F, Geerts H, Vergallo A; Alzheimer Precision Medicine Initiative (APMI).

J Alzheimers Dis. 2019;69(3):615-629. doi: 10.3233/JAD-190197.

Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga S, Fujishiro H, Takechi H.

J Alzheimers Dis. 2019;69(4):1031-1039. doi: 10.3233/JAD-190256.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias